Effects of Oxytocin on Reinforcement Learning

U

University of Electronic Science and Technology of China

Status

Unknown

Conditions

Learning Disabilities

Treatments

Drug: intranasal placebo
Drug: intranasal oxytocin

Study type

Interventional

Funder types

Other

Identifiers

NCT03846271
UESTC-neuSCAN-61

Details and patient eligibility

About

The main aim of the study is to investigate whether intranasal oxytocin (24IU) influences reward sensitivity and performance monitoring during reinforcement learning.

Full description

A double-blind, within-subject, placebo-controlled pharmacological EEG design will be employed. A total of 35 healthy male subjects will be recruited which will receive either intranasal placebo or oxytocin (24IU) on two separate study days (order counter-balanced, washout period at least 2 weeks). 45 minutes after treatment subjects will undergo a probabilistic feedback reinforcement learning paradigm with concurrent EEG acquisition. During the paradigm subjects will learn the reward probabilities of two different visual stimuli from probabilistic feedback provided by social stimuli (positive, negative emoticon). The paradigm includes an initial acquisition phase and a subsequent test phase.

Enrollment

40 estimated patients

Sex

Male

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age between 18-30
  • Male sex
  • Right handedness

Exclusion criteria

  • History of brain injury
  • Current or history of psychiatric, neurological or internist disorder
  • Current or regular use of medication, psychotropic substances, including nicotine
  • Contraindications for Oxytocin

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

40 participants in 2 patient groups

Oxytocin then placebo
Experimental group
Description:
Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
Treatment:
Drug: intranasal oxytocin
Drug: intranasal placebo
Placebo then oxytocin
Experimental group
Description:
Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
Treatment:
Drug: intranasal oxytocin
Drug: intranasal placebo

Trial contacts and locations

1

Loading...

Central trial contact

Benjamin Becker, PhD; Zhuang Qian, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems